Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05914103
Other study ID # 2023-1969
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date December 30, 2024

Study information

Verified date June 2023
Source Chinese Academy of Medical Sciences, Fuwai Hospital
Contact Fuxia Yan
Phone 13641158173
Email yanfuxia@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multicenter, stepwise design, cluster randomized controlled trial. Random sequence is generated by computer, and each center enters the intervention expectation (Phase I) in random order to implement ERAS strategy. If it does not enter the intervention expectation (Phase C) center, clinical diagnosis and treatment will be completed according to the traditional scheme. Among children, patients aged 28 to 6 who underwent cardiac surgery were included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative comfort for the patient, preoperative oral sugary beverage, continuous infusion of dexmedetomidine, multimodal analgesia, blood protection strategies, prevention of postoperative nausea and vomiting, intraoperative insulation, early tracheal extubation and intubation, and targeted liquid therapy. The traditional plan group follows the current clinical diagnosis and treatment routine. By comparing the differences in the incidence of major postoperative outcomes (MACE events, major pulmonary complications, and acute kidney injury) between the intervention group and the non intervention group, as well as comparing other adverse events (including but not limited to pneumonia, massive bleeding, postoperative arrhythmia, incision infection, postoperative nausea, vomiting, and delirium), all cause secondary intubation, and all cause secondary surgery between the two groups, and recording hospitalization time, ICU stay time The removal time of tracheal intubation and drainage tube, the pain score during hospitalization, the total amount of opioid drug use (converted to the same dose of morphine), hospitalization expenses, and family satisfaction scores were recorded to explore whether the ERAS regimen can reduce the incidence of major postoperative adverse events, improve patient prognosis, and accelerate postoperative recovery compared to traditional regimens.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 3030
Est. completion date December 30, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 28 Days to 6 Years
Eligibility Inclusion Criteria: - Patients aged 28 days to 6 years - Patients awaiting elective cardiac surgery with cardiopulmonary bypass (CPB). Exclusion Criteria: - The risk adjustment for congenital heart surgery (RACHS) is above class 5 - Patients with cardiac assist device, mechanical ventilation or the history of asphyxia - Patients with pulmonary disease, including respiratory tract infections and asthma - Patients with severe liver or renal dysfunction, including severe acute or chronic renal dysfunction need renal replacement therapy, and acute or chronic liver failure need artificial liver therapy - Fetal malformation includes polysplenia syndrome, Asplenia Syndrome, Down syndrome, DiGeoge syndrome, Marfan syndrome, trachea-bronchus stricture, diabetes, nervous functioning disorders, genital system malformations, imperforate anus, and Williams syndrome - Current enrollment in another clinical trial - Guardian's refusal or low adherence

Study Design


Intervention

Procedure:
ERAS
The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)

Locations

Country Name City State
China Fuwai hospital Beijing Beijing
China Fuwai hospital China Beijing

Sponsors (5)

Lead Sponsor Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital Beijing Anzhen Hospital, Fuwai Yunnan Cardiovascular Hospital, Guangdong People's Hospital, Shanghai Children's Medical Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary composite outcomes The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI) during hospitalization, an average of 1 week, assessed up to 30 days
Secondary length of hospital stay From the date of admission until the date of discharging From the date of admission until the date of discharging, assessed up to 30 days
Secondary the duration of intensive care unit (ICU) stay Time from ICU admission to ICU discharge Time from ICU admission to ICU discharge, assessed up to 30 days
Secondary time to extubation The time from the end of operation to the removal of tracheal intubation The time from the end of operation to the removal of tracheal intubation, assessed up to 30 days
Secondary time to drainage removal The time from the end of operation to the removal of drainage tube The time from the end of operation to the removal of drainage tube, assessed up to 30 days
Secondary the rate of other complications The rate of other complications include delium, pneumonia, pneumothorax, hematorrhea and so on during hospitalization, an average of 1 week, assessed up to 30 days
Secondary the rate of reintubation for any cause The rate of reintubation for any cause during hospitalization, an average of 1 week, assessed up to 30 days
Secondary cumulative opioid dosage Total perioperative consumption of opioid analgesics during hospitalization, an average of 1 week, assessed up to 30 days
Secondary overall medical costs Total cost of patients during hospitalization during hospitalization, an average of 1 week, assessed up to 30 days
Secondary Satisfaction score A satisfaction rating using a 0-10 number scale (0=unsatisfactory, 10=satisfactory) the day before discharge, assessed up to 30 days
Secondary the cumulative incidence of death from any cause within 30 days and 1 year the cumulative incidence of death from any cause within 30 days and 1 year within 30 days and 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04963751 - ERAS in Pediatric & Adolescent Gynecology Preoperative Counseling N/A
Recruiting NCT04072419 - Application of Enhanced Recovery After Surgery for Congenital Esophageal Atresia During Perioperative Period
Recruiting NCT05564819 - Efficacy and Safety of Acetaminophen in Postoperative Pain Management of Infants Phase 1
Recruiting NCT05613439 - The Fast-track Centre for Hip and Knee Replacement Database
Completed NCT04543214 - Outcome of Enhanced Recovery After Surgery (ERAS) Protocols in Patients Undergoing Small Bowel Surgery
Not yet recruiting NCT05576766 - Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy N/A
Recruiting NCT05081804 - The Effect of Enhanced Recovery After Surgery (ERAS) for Cesarean Section on Neonatal Blood Glucose N/A
Completed NCT04538235 - Analgesic Non Inferiority of the Thoracic Bi-block in Comparison With Thoracic Epidural for VATS.
Not yet recruiting NCT05914090 - The Application of Enhanced Recovery After Surgery (ERAS) for Cardiovascular Surgery in Adult N/A
Recruiting NCT05541640 - Intraoperative Lidocaine Infusion and Surgery-induced Release of Pro-inflammatory Cytokines After Abdominal Surgery N/A
Not yet recruiting NCT05511194 - Safety and Efficacy of ERAS Therapeutic Protocol for Complicated Appendicitis in Children N/A
Recruiting NCT05528484 - Self-reported Outcomes of Patients in ERAS Nursing N/A
Recruiting NCT04596800 - Prehabilitation Plus ERAS Versus ERAS in Gynecologic Oncology: a Randomized Clinical Trial Phase 3
Completed NCT04648644 - Application of ERAS Protocol in Emergency Surgery
Completed NCT02949518 - Enhanced Recovery After Spine Surgery N/A
Active, not recruiting NCT06457100 - Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Surgery Phase 1/Phase 2
Recruiting NCT06137976 - Surgeon Perception of Gastric Decompression at Time of Gynecologic Laparoscopy N/A
Completed NCT06118593 - Why in Hospital After Wedge Resection
Active, not recruiting NCT06369194 - POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol
Recruiting NCT04576533 - Patients Undergoing Laparoscopic Colorectal Surgery Walk Out From Operating Room After Surgery ( WOFOR-C1 ) N/A